Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction o COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021

被引：0

作者：

Christie, Athalia ^{[1
]}

Henley, Jane ^{[1
]}

Mattocks, Linda ^{[1
]}

Fernando, Robyn ^{[1
]}

Lansky, Amy ^{[1
]}

Ahmad, Farida B. ^{[1
]}

Adjemian, Jennifer ^{[1
]}

Anderson, Robert N. ^{[1
]}

Binder, Alison M. ^{[1
]}

Carey, Kelly ^{[1
]}

Dee, Deborah L. ^{[1
]}

Dias, Taylor ^{[1
]}

Duck, William M. ^{[1
]}

Gaughan, Denise M. ^{[1
]}

Lyons, Brianna Casey ^{[1
]}

McNaghten, A. D. ^{[1
]}

Park, Meeyoung M. ^{[1
]}

Reses, Hannah ^{[1
]}

Rodgers, Loren ^{[1
]}

Van Santen, Katharina ^{[1
]}

Walker, David ^{[1
]}

Beach, Michael J. ^{[1
]}

机构：

[1] CDC, COVID 19 Response Team, Atlanta, GA 30333 USA

来源：

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2021年 / 70卷 / 23期

关键词：

D O I：

10.15585/mmwr.mm7023e2

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

What is already known about this topic? COVID-19 vaccination began in the United States in December 2020, and adults aged >65 years were prioritized in early phases. What is added by this report? By May 1,2021,82%, 63%, and 42% of adults aged >65, 50-64, and 18-49 years, respectively, had received >1 vaccine dose. From November 29-December 12, 2020 to April 18-May 1, 2021, the rate ratios of COVID-19 incidence, emergency department visits, hospital admissions, and deaths among adults aged >65 years (>70 years for hospitalizations) to adults aged 18-49 years declined 40%, 59%, 65%, and 66%, respectively. What are the implications for public health practice? The greater decline in COVID-19 morbidity and mortality in older adults, the age group with the highest vaccination rates, demonstrates the potential impact of increasing populationlevel vaccination coverage. © 2021. All Rights Reserved.

引用

页码：858 / 864

页数：7

共 9 条

[1]

CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]

[2]

COVID-19 Treatment Guidelines Panel, 2021, Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

[3] BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].

Dagan, Noa ;

Barda, Noam ;

Kepten, Eldad ;

Miron, Oren ;

Perchik, Shay ;

Katz, Mark A. ;

Hernan, Miguel A. ;

Lipsitch, Marc ;

Reis, Ben ;

Balicer, Ran D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423

[4] The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020 [J].

Dooling, Kathleen ;

Marin, Mona ;

Wallace, Megan ;

McClung, Nancy ;

Chamberland, Mary ;

Lee, Grace M. ;

Talbot, H. Keipp ;

Romero, Jose R. ;

Bell, Beth P. ;

Oliver, Sara E. .

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 69 (51-52) :1657-1660

[5]

Efron B., 1986, Statistical Science, V1, P54, DOI [DOI 10.1214/SS/1177013815, https://doi.org/10.1214/ss/1177013815]

[6] Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [J].

Haas, Eric J. ;

Angulo, Frederick J. ;

McLaughlin, John M. ;

Anis, Emilia ;

Singer, Shepherd R. ;

Khan, Farid ;

Brooks, Nati ;

Smaja, Meir ;

Mircus, Gabriel ;

Pan, Kaijie ;

Southern, Jo ;

Swerdlow, David L. ;

Jodar, Luis ;

Levy, Yeheskel ;

Alroy-Preis, Sharon .

LANCET, 2021, 397 (10287) :1819-1829

[7]

Raifman Julia, 2020, COVID-19 US State Policy Database

[8]

Rinott E, 2021, MMWR-MORBID MORTAL W, V70, P326, DOI 10.15585/mmwr.mm7009e3

[9]

Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1

← 1 →